AURKB and nonpapillary renal cell carcinoma: The overall survival analysis showed that ccRCC patients with high expression levels of AURKB (Figure 8(b)) and CCNA2 (Figure 8(c)) had poorer overall survival times than those with low expression levels (P < 0.05).